Published in Oncotarget on September 28, 2016
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol (2005) 4.62
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell (2003) 3.58
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J (1997) 3.38
New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res (2010) 2.82
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov (2012) 2.53
G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther (2004) 2.50
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 2.50
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med (2010) 2.44
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol (2010) 2.43
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Chromosome breakage after G2 checkpoint release. J Cell Biol (2007) 2.25
Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol (2000) 1.93
Checkpoint pathways come of age. Cell (1997) 1.92
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res (2001) 1.80
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol (2015) 1.80
Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res (2011) 1.78
Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A (2010) 1.71
Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol (2006) 1.68
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther (2009) 1.66
DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res (2008) 1.59
MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res (2011) 1.59
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther (2011) 1.51
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res (2010) 1.48
Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol (2012) 1.45
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther (2013) 1.45
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle (2012) 1.44
Roles of Chk1 in cell biology and cancer therapy. Int J Cancer (2013) 1.37
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 1.30
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res (2012) 1.25
Wee1 kinase as a target for cancer therapy. Cell Cycle (2013) 1.22
Kinetics of DNA double-strand break repair throughout the cell cycle as assayed by pulsed field gel electrophoresis in CHO cells. Int J Radiat Biol (1991) 1.17
Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint. Cancer Res (2008) 1.10
Pulsed-field gel electrophoretic analysis of DNA double-strand breaks in mammalian cells using photostimulable storage phosphor imaging. Int J Radiat Biol (1994) 1.07
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int (2012) 1.06
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica (2013) 1.06
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin Oncol (R Coll Radiol) (2014) 1.04
Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex. J Biol Chem (2003) 1.04
Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect (2010) 1.02
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res (2013) 0.95
Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2012) 0.93
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res (2015) 0.90
A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs (2009) 0.86
Will targeting Chk1 have a role in the future of cancer therapy? J Clin Oncol (2015) 0.85
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget (2014) 0.83
CHK it out! Blocking WEE kinase routs TP53 mutant cancer. Clin Cancer Res (2014) 0.81
HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1. Radiother Oncol (2013) 0.78
Wee1 and Chk1 - crosstalk between key players in replicative stress. Genes Cancer (2015) 0.76